There are multiple chapters near you. Select your preferred chapter.
The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for troriluzole for the treatment of adults with spinocerebellar ataxia (SCA).
The epilepsy treatment is now approved as an add-on therapy for patients aged ≥ 2 years, following an appeal against NICE’s initial rejection.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback